Trial Profile
Phase I trial of RG 2833 in patients with Friedreich's ataxia.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 May 2012
Price :
$35
*
At a glance
- Drugs RG 2833 (Primary)
- Indications Friedreich's ataxia
- Focus Adverse reactions; Pharmacokinetics
- 15 Mar 2012 Status changed from planning to recruiting, according to a Repligen Corporation media release.
- 02 May 2011 New trial record